Zithromax online research references









  • Single-oral-dose azithromycin prophylaxis against experimental streptococcal or staphylococcal aortic valve endocarditis.
  • Simultaneous high-performance liquid chromatography analysis of azithromycin and two of its metabolites in human tears and plasma.
  • Ocular levels of azithromycin.
  • Evaluation of the efficacy of atovaquone alone or in combination with azithromycin against acute murine toxoplasmosis.
  • Comparison of the serum and intracellular pharmacokinetics of azithromycin in healthy and diabetic volunteers.
  • Apoptosis, oxidative metabolism and interleukin-8 production in human neutrophils exposed to azithromycin: effects of Streptococcus pneumoniae.
  • In vitro comparative dynamics of modified-release clarithromycin and of azithromycin.
  • Retrospective evaluation of a potential interaction between azithromycine and warfarin in patients stabilized on warfarin.
  • A new therapeutic approach in the treatment of genital chlamydial infections. Azithromycin (Sumamed)
  • In vitro development of resistance to ceftriaxone, cefprozil and azithromycin in Streptococcus pneumoniae.
  • Azithromycin levels in cervical mucus and plasma after a single 1.0g oral dose for chlamydial cervicitis.
  • Activity of moxifloxacin by itself and in combination with ethambutol, rifabutin, and azithromycin in vitro and in vivo against Mycobacterium avium.
  • Chlamydia pneumoniae infection in circulating human monocytes is refractory to antibiotic treatment.
  • Microbiological evaluation of antibiotics for empirical therapy of community-acquired infections of the lower respiratory tract
  • Rx drugs
  • Rx drugs
  • Incidence and determinants of Pseudomonas aeruginosa infection among persons with HIV: association with hospital exposure.
  • In vitro susceptibility of recent clinical isolates of Chlamydia trachomatis to macrolides and tetracyclines.
  • Inoculation of two genotypes of Hemobartonella felis (California and Ohio variants) to induce infection in cats and the response to treatment with azithromycin.
  • Insights into the mechanism of azithromycin interaction with an Escherichia coli functional ribosomal complex.
  • Inhibitory activity of azithromycin on biofilm synthesis and synergism between azithromycin and fleroxacin on Pseudomonas aeruginosa in biofilms
  • Quantitative determination of the antibiotic azithromycin in human serum by high-performance liquid chromatography (HPLC)-atmospheric pressure chemical ionization mass spectrometry: correlation with a standard HPLC-electrochemical method.
  • Postantibiotic suppression effect of macrolides on the expression of flagellin in Pseudomonas aeruginosa and Proteus mirabilis.
  • Antimalarial activity of azithromycin, artemisinin and dihydroartemisinin in fresh isolates of Plasmodium falciparum in Thailand.
  • In vitro activity of midecamycin diacetate, a 16-membered macrolide, against Streptococcus pyogenes isolated in France, 1995-1999.
  • Rx drugs
  • Pelvic type of chronic recurrent multifocal osteomyelitis
  • Pneumococcal conjugate vaccine serotypes of Streptococcus pneumoniae isolates and the antimicrobial susceptibility of such isolates in children with otitis media.
  • Prevalence of primary Helicobacter pylori resistance to eight antimicrobial agents in a hospital in Madrid
  • Therapeutic responses to antibacterial drugs in vivax malaria.
  • Bioequivalence assessment of Azomycin (Julphar, UAE) as compared to Zithromax (Pfizer, USA)--two brands of azithromycin--in healthy human volunteers.
  • Pharmacokinetics of azithromycin and concentration in body fluids and bronchoalveolar cells in foals.
  • Effect of an acidic environment on the susceptibility of Helicobacter pylori to trospectomycin and other antimicrobial agents.
  • Effect of azithromycin plus rifampin versus that of azithromycin alone on the eradication of Chlamydia pneumoniae from lung tissue in experimental pneumonitis.
  • Antibiotic resistant N. gonorrhoeae in Trinidad and Tobago.
  • Endothelial cell compatibility of azithromycin and erythromycin.
  • High accuracy mass measurement of peptides with internal calibration using a dual electrospray ionization sprayer system for protein identification.
  • Rx drugs
  • Pharmacokinetics of azithromycin in foals after i.v. and oral dose and disposition into phagocytes.
  • Effect of gemifloxacin on viability of Chlamydia pneumoniae (Chlamydophila pneumoniae) in an in vitro continuous infection model.
  • Rx drugs
  • Experimental acute otitis media due to nontypeable Haemophilus influenzae: comparison of high and low azithromycin doses with placebo.
  • Rx drugs
  • Postantibiotic effects and postantibiotic sub-MIC effects of roxithromycin, clarithromycin, and azithromycin on respiratory tract pathogens.
  • Characterization of azithromycin hydrates.
  • Impact of single dose azithromycin on group A streptococci in the upper respiratory tract and skin of Aboriginal children.
  • Tendon or joint disorders in children after treatment with fluoroquinolones or azithromycin.
  • Clinical isolates of Staphylococcus aureus with ribosomal mutations conferring resistance to macrolides.
  • Bactericidal effect and pharmacodynamics of cethromycin (ABT-773) in a murine pneumococcal pneumonia model.
  • Effects of azithromycin on shiga toxin production by Escherichia coli and subsequent host inflammatory response.
  • Systematic screening for Chlamydia trachomatis with the molecular biological AMP-CT test in urine samples from young women
  • Isocratic liquid chromatographic method for the analysis of azithromycin and its structurally related substances in bulk samples.
  • Macrolide consumption according to geographic areas in the province of Valladolid
  • Mechanisms of azithromycin accumulation and efflux in human polymorphonuclear leukocytes
  • Cost-effectiveness analysis of five different antibiotic regimens for the treatment of uncomplicated Chlamydia trachomatis cervicitis.
  • Follicular conjunctivitis caused by Chlamydia trachomatis in an infant Saharan population: molecular and clinical diagnosis.
  • Lymphadenitis colli due to non-tuberculous mycobacteria (NTM): a case-series and review of the literature
  • Analysis of unknown compounds in azithromycin bulk samples with liquid chromatography coupled to ion trap mass spectrometry.
  • Summary of the clinical studies with azithromycin in the pediatric fields
  • Determination of intracellular efficacies of azithromycin against Leishmania major infection in human neutrophils in vitro.
  • Effects of an efflux mechanism and ribosomal mutations on macrolide susceptibility of Haemophilus influenzae clinical isolates.
  • Effect of carbon dioxide on testing of susceptibilities of respiratory tract pathogens to macrolide and azalide antimicrobial agents.
  • Structural basis for the antibiotic activity of ketolides and azalides.
  • Activity of telithromycin (HMR 3647) against anaerobic bacteria compared to those of eight other agents by time-kill methodology.
  • Should we offer antibiotic prophylaxis post sexual assault?
  • Ocular pharmacokinetics of orally administered azithromycin in rabbits.
  • Antibiotic therapy for ambulatory patients with community-acquired pneumonia in an emergency department setting.
  • Influence of P-glycoprotein and MRP efflux pump inhibitors on the intracellular activity of azithromycin and ciprofloxacin in macrophages infected by Listeria monocytogenes or Staphylococcus aureus.
  • In vitro susceptibilities of Rhodococcus equi and other common equine pathogens to azithromycin, clarithromycin, and 20 other antimicrobials.
  • Does the diagnosis of trachoma adequately identify ocular chlamydial infection in trachoma-endemic areas?
  • Eliminating trachoma in areas with limited disease.
  • Chlamydia pneumoniae resists antibiotics in lymphocytes.
  • Pharmacodynamic activity of azithromycin against macrolide-susceptible and -resistant Streptococcus pneumoniae simulating clinically achievable free serum, epithelial lining fluid and middle ear fluid concentrations.
  • Azithromycin-induced block of elementary body formation in Chlamydia trachomatis.
  • The macrolide antibiotic azithromycin interacts with lipids and affects membrane organization and fluidity: studies on Langmuir-Blodgett monolayers, liposomes and J774 macrophages.
  • In vitro activities of azithromycin and ofloxacin against Chlamydia pneumoniae in a continuous-infection model.
  • Post-antibiotic effect of azithromycin and erythromycin on streptococcal susceptibility to phagocytosis.
  • Impact of azithromycin administration for trachoma control on the carriage of antibiotic-resistant Streptococcus pneumoniae.
  • Antimicrobial activities of macrolides against recent clinical isolates, and analysis of resistant mechanisms
  • Interaction of macrolides and ketolides with the phagocytic cell line PLB-985.
  • Influence of outer membrane mutations on susceptibility of Escherichia coli to the dibasic macrolide azithromycin.
  • Potentiation of antibacterial activity of azithromycin and other macrolides by normal human serum.
  • In vitro evaluation of activities of azithromycin, erythromycin, and tetracycline against Chlamydia trachomatis and Chlamydia pneumoniae.
  • Once-a-week azithromycin in AIDS patients: tolerability, kinetics, and effects on zidovudine disposition.
  • In vitro activities of azithromycin, clarithromycin, L-ofloxacin, and other antibiotics against Chlamydia pneumoniae.
  • Activity of azithromycin (CP-62,993) and erythromycin against chloroquine-sensitive and chloroquine-resistant strains of Plasmodium falciparum in vitro.
  • In vitro activity of azithromycin compared with that of erythromycin against Actinobacillus actinomycetemcomitans.
  • Erythromycin inhibits the assembly of the large ribosomal subunit in growing Escherichia coli cells.
  • Inhibition of motility of Pseudomonas aeruginosa and Proteus mirabilis by subinhibitory concentrations of azithromycin.
  • The in vitro profile of selected 14-membered azalides.
  • Azithromycin pharmacokinetics and penetration to lymph.
  • The evaluation of the efficacy of azithromycin and pyrimethamine used alone or in combination in the treatment of an experimental infection in mice by Toxoplasma gondii
  • Nutritionally variant streptococcal infections at a University Hospital in Taiwan: disease emergence and high prevalence of beta-lactam and macrolide resistance.
  • Activity of azithromycin against cryptosporidia in immunosuppressed rats.
  • Activities of various macrolide antibiotics against Mycobacterium leprae infection in mice.
  • Decreased azithromycin susceptibility of Neisseria gonorrhoeae due to mtrR mutations.
  • Prophylactic and therapeutic activities of azithromycin in a mouse model of pneumococcal pneumonia.
  • Synergistic activity of azithromycin and gamma interferon in murine toxoplasmosis.
  • Pharmacokinetics of macrolides. Comparison of plasma, tissue and free concentrations with special reference to roxithromycin.
  • Tissue penetration properties of macrolide antibiotics--comparative tissue distribution of erythromycin-stearate, clarithromycin, roxithromycin and azithromycin in rats
  • Influence of the test medium on azithromycin and erythromycin regression statistics.
  • Azithromycin levels in plasma and gastric tissue, juice and mucus.
  • A modified broth dilution assay for antibiotic sensitivity testing of Mycobacterium avium-intracellulare using paraffin slide cultures.
  • Stimulation with cytokines enhances penetration of azithromycin into human macrophages.
  • Concentration of azithromycin in human prostatic tissue.
  • Chlamydia trachomatis: in vitro susceptibility of genital and ocular isolates to some quinolones, amoxicillin and azithromycin.
  • Comparative in vitro activity of azithromycin, clarithromycin, erythromycin and lomefloxacin against Mycoplasma pneumoniae, Mycoplasma hominis and Ureaplasma urealyticum.
  • Antimicrobial interference with bacterial mechanisms of pathogenicity: effect of sub-MIC azithromycin on gonococcal piliation and attachment to human epithelial cells.
  • Efficacy of azithromycin in the treatment of guinea pigs infected with Legionella pneumophila by aerosol.
  • Inhibition of cytoplasmic and organellar protein synthesis in Toxoplasma gondii. Implications for the target of macrolide antibiotics.
  • Oral rifampin plus azithromycin or clarithromycin to treat osteomyelitis in rabbits.
  • Comparative in-vitro activity of azithromycin and erythromycin against Gram-positive cocci, Haemophilus influenzae and anaerobes.
  • In-vitro and in-vivo susceptibility of Borrelia burgdorferi to azithromycin.
  • Correlation of the extravascular pharmacokinetics of azithromycin with in-vivo efficacy in models of localized infection.
  • Relationship of high tissue concentrations of azithromycin to bactericidal activity and efficacy in vivo.
  • Activity of azithromycin and roxithromycin alone or in combination against Mycobacterium avium and Mycobacterium xenopi
  • Mechanism of azithromycin uptake in human polymorphonuclear leucocytes.
  • Spectrum and mode of action of azithromycin (CP-62,993), a new 15-membered-ring macrolide with improved potency against gram-negative organisms.
  • In vitro susceptibilities of Entamoeba histolytica to azithromycin, CP-63,956, erythromycin, and metronidazole.
  • Chlamydia trachomatis genitourinary infections: laboratory diagnosis and therapeutic aspects. Evaluation of in vitro and in vivo effectiveness of azithromycin.
  • Activity of azithromycin as a blood schizonticide against rodent and human plasmodia in vivo.
  • Distribution of orally administered azithromycin in various blood compartments.
  • Comparative activities of azithromycin and clarithromycin against Mycobacterium avium infection in beige mice.
  • Intermittent azithromycin for treatment of Mycobacterium avium infection in beige mice.
  • Mycobacterium avium strains resistant to clarithromycin and azithromycin.
  • Rifabutin and sparfloxacin but not azithromycin inhibit binding of Mycobacterium avium complex to HT-29 intestinal mucosal cells.
  • Comparison of mutants of Toxoplasma gondii selected for resistance to azithromycin, spiramycin, or clindamycin.
  • Effect of CO2 on susceptibilities of anaerobes to erythromycin, azithromycin, clarithromycin, and roxithromycin.
  • Azithromycin-omeprazole. Treatment for the eradication of Helicobacter pylori
  • Pharmacokinetic and in vivo studies with azithromycin (CP-62,993), a new macrolide with an extended half-life and excellent tissue distribution.
  • A new model examining intracellular and extracellular activity of amoxicillin, azithromycin, and clarithromycin in infected cells.
  • In vitro evaluation of activities of azithromycin, clarithromycin and sparfloxacin against Chlamydia trachomatis.
  • Erythromycin, clarithromycin, and azithromycin: use of frequency distribution curves, scattergrams, and regression analyses to compare in vitro activities and describe cross-resistance.
  • Azithromycin inhibition of intracellular Legionella micdadei.
  • In-vitro activity of azithromycin on Chlamydia trachomatis infected, polarized human endometrial epithelial cells.
  • Azithromycin, rifabutin, and rifapentine for treatment and prophylaxis of Mycobacterium avium complex in rats treated with cyclosporine.
  • Effect of pH variation on the susceptibility of Helicobacter pylori to three macrolide antimicrobial agents and temafloxacin.
  • In vitro activity of azithromycin against bacterial enteric pathogens.
  • Antimalarial activity of azithromycin and erythromycin against Plasmodium berghei.
  • Comparison of azithromycin, roxithromycin, and cephalexin penetration kinetics in early and mature abscesses.
  • In vitro activities of azithromycin (CP 62,993), clarithromycin (A-56268; TE-031), erythromycin, roxithromycin, and clindamycin.
  • The comparative activity of azithromycin, macrolides and amoxycillin against streptococci in experimental infections.
  • Comparison of the pharmacokinetics of three-day and five-day regimens of azithromycin in plasma and urine.
  • Tapetal effect of an azalide antibiotic following oral administration in beagle dogs.
  • An economic evaluation of screening for Chlamydia trachomatis in adolescent males.
  • The particular case of azalides: antibiotic diapedesis. Experimental data from a murine model of pneumococcal pneumonia
  • In vivo efficacy of azithromycin in treatment of systemic infection and septic arthritis induced by type IV group B Streptococcus strains in mice: comparative study with erythromycin and penicillin G.
  • Comparative pharmacodynamics of clarithromycin and azithromycin against respiratory pathogens.
  • Efficacy of azithromycin and rifabutin in preventing infection by Mycobacterium avium complex in beige mice.
  • Azithromycin for the cure of Helicobacter pylori infection.
  • Azithromycin in the prophylaxis of opportunistic infections in AIDS.
  • In vitro comparison of the activity of doxycycline, tetracycline, erythromycin and a new macrolide, CP 62993, against Mycoplasma pneumoniae, Mycoplasma hominis and Ureaplasma urealyticum.
  • Effect of recombinant human gamma interferon on intracellular activities of antibiotics against Listeria monocytogenes in the human macrophage cell line THP-1.
  • Haemophilus influenzae type b exoproducts induce chemotaxis and macrolide antibiotic release by human polymorphonuclear leukocytes.
  • In vitro activities of azithromycin, clarithromycin, erythromycin, and tetracycline against 13 strains of Chlamydia pneumoniae.
  • Susceptibility of macrolide and beta-lactam antibiotics of Streptococcus pyogenes strains isolated over a four-year period in central Italy.
  • Azithromycin for the treatment of acne.
  • Inadequate azithromycin activity against Brucella melitensis in mice with acute or chronic infections.
  • Comparative activities of clarithromycin, erythromycin, and azithromycin against penicillin-susceptible and penicillin-resistant pneumococci.
  • In vitro susceptibility of thirty Borrelia strains from various sources against eight antimicrobial chemotherapeutics.
  • Influence of subinhibitory concentrations of ceftazidime, ciprofloxacin and azithromycin on the morphology and adherence of P-fimbriated escherichia coli.
  • Properties of azithromycin that enhance the potential for compliance in children with upper respiratory tract infections.
  • Comparative studies on the effects of erythromycin A and azithromycin upon extracellular release of lysosomal enzymes in inflammatory processes.
  • Comparison of Etest to broth microdilution method for testing Streptococcus pneumoniae susceptibility to levofloxacin and three macrolides.
  • In vitro activities of azithromycin, clarithromycin, and other antibiotics against Chlamydia pneumoniae.
  • Clinico-laboratory evaluation of the effectiveness of azithromycin in the treatment of patients with Chlamydia and mixed Chlamydia-gonorrhea infections
  • Interaction of the macrolide azithromycin with phospholipids. II. Biophysical and computer-aided conformational studies.
  • The influence of azithromycin on the biofilm formation of Pseudomonas aeruginosa in vitro.
  • Clinical studies on azithromycin in pediatrics
  • Depression of the N-demethylation of erythromycin, azithromycin, clarithromycin and clindamycin in murine Toxoplasma infection.
  • Pharmacokinetic, bacteriological and clinical studies on azithromycin in children
  • Requirements for intracellular accumulation and release of clarithromycin and azithromycin by human phagocytes.
  • Antimicrobial activity of RU-66647, a new ketolide.
  • In vitro activity of azithromycin (CP-62,993), a novel macrolide, against enteric pathogens.
  • Comparison of E-test with agar dilution methods in testing susceptibility of N. gonorrhoeae to azithromycin.
  • Azithromycin in the treatment of pneumonias caused by Chlamydia spp: a retrospective study.
  • Delivery of azithromycin to Chlamydia trachomatis-infected polarized human endometrial epithelial cells by polymorphonuclear leucocytes.
  • Azithromycin in the treatment of chlamydial cervicitis and eradication of Ureaplasma urealyticum in female lower genital tract.
  • Intracellular activity of azithromycin against Mycobacterium avium complex in human macrophages.
  • Susceptibility of penicillin-susceptible and -resistant pneumococci to dirithromycin compared with susceptibilities to erythromycin, azithromycin, clarithromycin, roxithromycin, and clindamycin.
  • In vitro activity of trovafloxacin against Chlamydia pneumoniae.
  • Cellular accumulation of the new ketolide RU 64004 by human neutrophils: comparison with that of azithromycin and roxithromycin.
  • Studies of the killing kinetics of benzylpenicillin, cefuroxime, azithromycin, and sparfloxacin on bacteria in the postantibiotic phase.
  • A plastid organelle as a drug target in apicomplexan parasites.
  • Efficacy and tolerance of azithromycin in respiratory tract infections in children
  • A school-based Chlamydia control program using DNA amplification technology.
  • A new semi-solid agar dilution method for determining amoxycillin, clarithromycin and azithromycin MICs for Helicobacter pylori isolates.
  • Susceptibility of Chlamydia pneumoniae to azithromycin and doxycycline: methodological aspects on the determination of minimal inhibitory and minimal bactericidal concentrations.
  • Potentiation of antifungal activity of amphotericin B by azithromycin against Aspergillus species.
  • The postantibiotic effect of azithromycin on respiratory pathogens
  • Short-term (6 days) eradication of Helicobacter pylori infection in the practice of a health insurance physician
  • Trends in antibiotic resistance among diarrheal pathogens isolated in Thailand over 15 years.
  • Cost-effectiveness of sparfloxacin compared with other oral antimicrobials in outpatient treatment of community-acquired pneumonia.
  • Treatment of atypical pneumonia with azithromycin: comparison of a 5-day and a 3-day course.
  • Activity of azithromycin, clarithromycin, roxithromycin, dirithromycin, quinupristin/dalfopristin and erythromycin against Legionella species by intracellular susceptibility testing in HL-60 cells.
  • A cost-effectiveness analysis of screening and treatment for Chlamydia trachomatis infection in asymptomatic women.
  • In vitro activity of oral antimicrobial agents against clinical isolates of Pasteurella multocida.
  • Azithromycin impact on neutrophil oxidative metabolism depends on exposure time.
  • The evaluation of the clinical efficacy and tolerance of azithromycin in odontostomatological infections
  • Computer-aided prediction of macrolide antibiotic concentrations in human circulating polymorphonuclear leucocytes.
  • Postantibiotic effect and postantibiotic sub-MIC effect of levofloxacin compared to those of ofloxacin, ciprofloxacin, erythromycin, azithromycin, and clarithromycin against 20 pneumococci.
  • Comparison of in vitro activity of azithromycin and ampicillin against 31 isolates of Streptococcus milleri.
  • Gastric mucosal distribution and clinical efficacy of azithromycin in patients with Helicobacter pylori related gastritis.
  • Combination drug therapy for cryptosporidiosis in AIDS.
  • Indirect inhibition by antibiotics of nucleotide and deoxynucleotide biosynthesis in Plasmodium falciparum.
  • Macrolide antibiotic inhibition of translation and 50S ribosomal subunit assembly in methicillin-resistant Staphylococcus aureus cells.
  • Accumulation, release and subcellular localization of azithromycin in phagocytic and non-phagocytic cells in culture.







    DreamPharm: Herbal and Nutritional supplements online || Hair Million herbal formula for hair loss and hair growth || Antibiotics and prescription medications online literature ||